Palleon is advancing a suite of platform technologies that uniquely enable drug development in glyco-immunology. Palleon’s EAGLE platform employs a novel strategy of enzymatic sialoglycan degradation which overcomes intractable biological redundancy and enables a uniquely pan-immune anti-tumor response to address patient populations who are resistant to first generation immuno-oncology drugs. Palleon’s HYDRA translational ...
Palleon is advancing a suite of platform technologies that uniquely enable drug development in glyco-immunology. Palleon’s EAGLE platform employs a novel strategy of enzymatic sialoglycan degradation which overcomes intractable biological redundancy and enables a uniquely pan-immune anti-tumor response to address patient populations who are resistant to first generation immuno-oncology drugs. Palleon’s HYDRA translational platform characterizes cancer patients by their tumor surface glycan profile to identify populations that have tumors that utilize this mechanism.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.